This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sparano, J. A. Articles by Paik, S. Search for Related Content PubMed PubMed Citation Articles by Sparano, J. A. Articles by Paik, S. Social Bookmarking                            What's this?

Development of the 21-Gene Assay and Its Application in Clinical Practice and Clinical Trials

Joseph A. Sparano, Soonmyung Paik

From the Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; and the Division of Pathology, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA

Corresponding author: Joseph A. Sparano, MD, Montefiore Medical Center-Weiler Division, 1825 Eastchester Rd, Bronx, NY 10461; e-mail: jsparano{at}montefiore.org

Several multigene markers that predict relapse more accurately than classical clinicopathologic features have been developed. The 21-gene assay was developed specifically for patients with estrogen receptor (ER)–positive breast cancer, and has been shown to predict distant recurrence more accurately that classical clinicopathologic features in patients with ER-positive breast cancer and negative axillary nodes treated with adjuvant tamoxifen; validation studies in this population led to its approval as a diagnostic test. In a similar population, it also may be used to assess the benefit of adding chemotherapy to hormonal therapy. Other validation studies indicate that it also predicts the risk of distant and local recurrence in other populations with ER-positive disease, including node-negative patients receiving no adjuvant therapy and patients with positive axillary nodes treated with doxorubicin-containing chemotherapy. The Trial Assigning Individualized Options for Treatment (TAILORx) is multicenter trial that integrates the 21-gene assay into the clinical decision-making process and is designed to refine the utility of the assay in clinical practice and to provide a resource for evaluating additional molecular markers as they are developed in the future.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. M. Kelly, E. Warner, D. T. Tsoi, S. Verma, and K. I. Pritchard Review of the Clinical Studies Using the 21-Gene Assay Oncologist, May 1, 2010; 15(5): 447 - 456. [Abstract] [Full Text] [PDF]

				D. Fumagalli and C. Sotiriou Personalized Medicine for Breast Cancer Patients Am. Assoc. Cancer Res. Educ. Book, April 17, 2010; 2010(1): 131 - 134. [Full Text] [PDF]

				J. Subramanian and R. Simon Gene Expression-Based Prognostic Signatures in Lung Cancer: Ready for Clinical Use? J Natl Cancer Inst, April 7, 2010; 102(7): 464 - 474. [Abstract] [Full Text] [PDF]

				J. A. Sparano and L. J. Solin Defining the Clinical Utility of Gene Expression Assays in Breast Cancer: The Intersection of Science and Art in Clinical Decision Making J. Clin. Oncol., April 1, 2010; 28(10): 1625 - 1627. [Full Text] [PDF]

				S. R. D. Johnston New Strategies in Estrogen Receptor-Positive Breast Cancer Clin. Cancer Res., April 1, 2010; 16(7): 1979 - 1987. [Abstract] [Full Text] [PDF]

				E. S. Knudsen and J. Y. J. Wang Targeting the RB-pathway in Cancer Therapy Clin. Cancer Res., February 15, 2010; 16(4): 1094 - 1099. [Abstract] [Full Text] [PDF]

				H. Colman, L. Zhang, E. P. Sulman, J. M. McDonald, N. L. Shooshtari, A. Rivera, S. Popoff, C. L. Nutt, D. N. Louis, J. G. Cairncross, et al. A multigene predictor of outcome in glioblastoma Neuro Oncology, January 1, 2010; 12(1): 49 - 57. [Abstract] [Full Text] [PDF]

				A. C. Culhane, T. Schwarzl, R. Sultana, K. C. Picard, S. C. Picard, T. H. Lu, K. R. Franklin, S. J. French, G. Papenhausen, M. Correll, et al. GeneSigDB--a curated database of gene expression signatures Nucleic Acids Res., January 1, 2010; 38(suppl_1): D716 - D725. [Abstract] [Full Text] [PDF]

				J. A. Sparano, L. J. Goldstein, B. H. Childs, S. Shak, D. Brassard, S. Badve, F. L. Baehner, R. Bugarini, S. Rowley, E. Perez, et al. Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer Clin. Cancer Res., December 15, 2009; 15(24): 7693 - 7700. [Abstract] [Full Text] [PDF]

				J. M. Bueno-de-Mesquita, G. S. Sonke, M. J. van de Vijver, and S. C. Linn Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice Ann. Onc., December 2, 2009; (2009) mdp547v1. [Abstract] [Full Text] [PDF]

				M. Cianfrocca and W. Gradishar New Molecular Classifications of Breast Cancer CA Cancer J Clin, September 1, 2009; 59(5): 303 - 313. [Abstract] [Full Text] [PDF]

				S. J. Mandrekar and D. J. Sargent Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges J. Clin. Oncol., August 20, 2009; 27(24): 4027 - 4034. [Abstract] [Full Text] [PDF]

				L. Shi, B. Dong, Z. Li, Y. Lu, T. Ouyang, J. Li, T. Wang, Z. Fan, T. Fan, B. Lin, et al. Expression of ER-{alpha}36, a Novel Variant of Estrogen Receptor {alpha}, and Resistance to Tamoxifen Treatment in Breast Cancer J. Clin. Oncol., July 20, 2009; 27(21): 3423 - 3429. [Abstract] [Full Text] [PDF]

				J. Hugh, J. Hanson, M. C. U. Cheang, T. O. Nielsen, C. M. Perou, C. Dumontet, J. Reed, M. Krajewska, I. Treilleux, M. Rupin, et al. Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial J. Clin. Oncol., March 10, 2009; 27(8): 1168 - 1176. [Abstract] [Full Text] [PDF]

				C. Sotiriou and L. Pusztai Gene-Expression Signatures in Breast Cancer N. Engl. J. Med., February 19, 2009; 360(8): 790 - 800. [Full Text] [PDF]

				M. Schmidt, A. Victor, D. Bratzel, D. Boehm, C. Cotarelo, A. Lebrecht, W. Siggelkow, J. G. Hengstler, A. Elsasser, M. Gehrmann, et al. Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer--comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial Ann. Onc., February 1, 2009; 20(2): 258 - 264. [Abstract] [Full Text] [PDF]

				M. Dowsett and A. K. Dunbier Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer Clin. Cancer Res., December 15, 2008; 14(24): 8019 - 8026. [Abstract] [Full Text] [PDF]

				C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers Clin. Chem., December 1, 2008; 54(12): e11 - e79. [Abstract] [Full Text] [PDF]